glp-1 and mash Liver gains beyond glycemic control: vs. SGLT2 in metabolic dysfunction–associated steatohepatitis (MASH): A real-world data analysis Novo Nordisk leads MASH therapeutic

Future studies should thus consider atypical scores and baseline inflammatory markers for pre-stratified designs

Molecular mechanism for changes in proteoglycan binding on compositional changes of the core and the surface of low-density lipoprotein-containing human apolipoprotein B100

In my opinion, we have bigger issues than judging anyone for taking or not taking a drug

Neuroscience 164 , 747759 (2009)

Daniell, and Yangs coauthors on the paper, all from Penn Dental Medicine, were first author Jiyoung Park, Guangqi Yan, Kwang-Chul Kwon, Min Liu, and Patricia A

Flavin Monooxygenase 3, the Host Hepatic Enzyme in the Metaorganismal Trimethylamine N-Oxide-Generating Pathway, Modulates Platelet Responsiveness and Thrombosis Risk